Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.01 USD
Change Today +0.02 / 1.01%
Volume 380.9K
BLRX On Other Exchanges
Symbol
Exchange
OTC US
NASDAQ CM
Stuttgart
Tel Aviv
As of 4:30 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

biolinerx ltd-spons adr (BLRX) Snapshot

Open
$2.04
Previous Close
$1.99
Day High
$2.10
Day Low
$1.95
52 Week High
03/5/15 - $3.28
52 Week Low
11/28/14 - $1.20
Market Cap
107.5M
Average Volume 10 Days
448.6K
EPS TTM
--
Shares Outstanding
53.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOLINERX LTD-SPONS ADR (BLRX)

biolinerx ltd-spons adr (BLRX) Related Businessweek News

No Related Businessweek News Found

biolinerx ltd-spons adr (BLRX) Details

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company’s development pipeline consists of clinical-stage therapeutic candidates, including BL-1040, a novel polymer solution for use in the prevention of ventricular remodeling following an acute myocardial infarction; BL-8040, a novel peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications; BL-7010, a novel polymer for the treatment of celiac disease; BL-5010, a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease; and BL-8020, an orally available treatment for the hepatitis C virus and other viral indications. It also has four therapeutic candidates in the preclinical stages of development, including BL-8030 for the treatment of Hepatitis C; BL-9010 to treat severe allergies and asthma; BL-9020 for the treatment of type 1 diabetes; and BL-1110 for the treatment of neuropathic pain and scleroderma. The company has strategic collaboration with Novartis Pharma AG for the co-development of drug candidates. BioLineRx Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

46 Employees
Last Reported Date: 03/23/15
Founded in 2003

biolinerx ltd-spons adr (BLRX) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: $366.0K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $269.0K
Vice President of Business Development
Total Annual Compensation: $241.0K
Vice President of Medical Affairs
Total Annual Compensation: $185.0K
Chief Scientific Officer
Total Annual Compensation: $215.0K
Compensation as of Fiscal Year 2014.

biolinerx ltd-spons adr (BLRX) Key Developments

BioLineRx Initiates Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid Leukemia

BioLineRx, Ltd. announced the completion of the dose escalation stage of its ongoing Phase 2 study of BL-8040, and commencement of the expansion stage at the optimal dose of this novel treatment for acute myeloid leukemia (AML). Top-line results from the study are anticipated in the fourth quarter of 2015. Results of the completed dose escalation stage, in which 22 patients participated, showed that all BL-8040 tested doses, up to 1.5 mg/kg, were found to be safe and well tolerated when administered in combination with Ara-C (Cytarabine). Building upon prior interim results, which included doses up to 1.25 mg/kg and were presented at the 2014 American Society for Hematology conference, the data indicate that BL-8040 exhibits robust single-agent activity, with a dramatic decrease in the amount of AML cells in the bone marrow and significant mobilization of these cells into the peripheral blood following two days of BL-8040 monotherapy, as well as direct induction of leukemia cell death. Based on the study’s pharmacodynamic data, 1.5 mg/kg was chosen as the dose for use in the expansion stage of the study. In parallel to initiation of the expansion stage, additional patients will be recruited to assess one higher dose level of BL-8040, in order to further expand the therapeutic window of the drug.

BioLineRx, Ltd. Proposes to Amend the Articles of Association

BioLineRx, Ltd. proposed to amend the Articles of Association of the company at its EGM to be held on May 31, 2015.

BioLineRx, Ltd. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

BioLineRx, Ltd. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported operating loss of ILS 61,719,000 compared to ILS 61,383,000 a year ago. Financial income was ILS 12,754,000 compared to ILS 2,600,000 a year ago. Net and comprehensive loss for the period was ILS 39,620,000 compared to ILS 61,438,000 a year ago. Basic and diluted loss per share were ILS 0.12 compared to ILS 0.27 a year ago. Net cash used in operating activities was ILS 56,383,000 compared to ILS 70,464,000 a year ago. Purchase of property and equipment was ILS 674,000 compared to ILS 309,000 a year ago. Additions to intangible assets were ILS 21,000 compared to ILS 99,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLRX:US $2.01 USD +0.02

BLRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BLRX.
View Industry Companies
 

Industry Analysis

BLRX

Industry Average

Valuation BLRX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOLINERX LTD-SPONS ADR, please visit www.biolinerx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.